Synthaverse Valuation

Is SVE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SVE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SVE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SVE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SVE?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SVE. This is calculated by dividing SVE's market cap by their current preferred multiple.
What is SVE's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	zł324.66m

SVE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.4x
Enterprise Value/EBITDA	28.4x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does SVE's PE Ratio compare to its peers?

The above table shows the PE ratio for SVE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	25x
MAB Mabion	7.3x	-101.6%	zł274.1m
GEN Genomed Spólka Akcyjna	62.8x	n/a	zł37.0m
SLV Selvita	18x	15.9%	zł1.2b
BGD Biogened	11.9x	n/a	zł63.9m
SVE Synthaverse	89.1x	n/a	zł322.5m

Price-To-Earnings vs Peers: SVE is expensive based on its Price-To-Earnings Ratio (89.1x) compared to the peer average (25x).

Price to Earnings Ratio vs Industry

How does SVE's PE Ratio compare vs other companies in the European Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: SVE is expensive based on its Price-To-Earnings Ratio (89.1x) compared to the European Biotechs industry average (27.6x).

Price to Earnings Ratio vs Fair Ratio

What is SVE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SVE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	89.6x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SVE's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.